Surgery Partners (NASDAQ:SGRY) Issues Quarterly Earnings Results

Surgery Partners (NASDAQ:SGRY - Get Free Report) announced its quarterly earnings data on Monday. The company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.38 by $0.01, Zacks reports. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. The business had revenue of $864.40 million during the quarter, compared to analyst estimates of $828.09 million. Surgery Partners updated its FY 2025 guidance to EPS.

Surgery Partners Stock Performance

Surgery Partners stock traded up $0.19 during trading on Thursday, reaching $24.16. The company had a trading volume of 1,017,510 shares, compared to its average volume of 1,058,561. The firm's 50-day simple moving average is $23.21 and its 200 day simple moving average is $26.36. Surgery Partners has a 52 week low of $19.50 and a 52 week high of $33.97. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99. The firm has a market capitalization of $3.07 billion, a price-to-earnings ratio of -50.33, a price-to-earnings-growth ratio of 19.21 and a beta of 2.60.

Insiders Place Their Bets

In other news, CEO Jason Eric Evans sold 26,520 shares of the firm's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $25.65, for a total transaction of $680,238.00. Following the sale, the chief executive officer now directly owns 560,698 shares in the company, valued at $14,381,903.70. This trade represents a 4.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO David T. Doherty sold 13,641 shares of the company's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $25.61, for a total transaction of $349,346.01. Following the completion of the transaction, the chief financial officer now directly owns 108,862 shares of the company's stock, valued at $2,787,955.82. This represents a 11.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 96,733 shares of company stock worth $2,480,106 over the last quarter. 2.30% of the stock is currently owned by corporate insiders.

Remove Ads

Analyst Ratings Changes

A number of brokerages recently issued reports on SGRY. Macquarie reissued an "outperform" rating and set a $34.00 price target on shares of Surgery Partners in a research report on Tuesday, November 19th. Bank of America began coverage on shares of Surgery Partners in a report on Monday, December 16th. They set a "buy" rating and a $30.00 target price for the company. JPMorgan Chase & Co. cut their price target on Surgery Partners from $38.00 to $28.00 and set a "neutral" rating on the stock in a research note on Tuesday, December 3rd. Finally, Royal Bank of Canada lowered their price objective on Surgery Partners from $49.00 to $35.00 and set an "outperform" rating for the company in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Surgery Partners currently has a consensus rating of "Moderate Buy" and a consensus price target of $36.56.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.